Related Experiment Video
Updated: Jul 14, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
[Relationship between single nucleotide polymorphisms of paraoxonase 2 and stroke]
Hong-wei Xu1, Zhen Zhao, Ning Yuan
1Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008 PR China.
Summary
Genetic variations in paraoxonase 2 (PON2) were investigated for their association with stroke. The study found no significant correlation between PON2 polymorphisms and stroke risk in the studied Chinese population.
Area of Science:
- Genetics
- Neurology
- Molecular Biology
Background:
- Stroke is a leading cause of death and disability worldwide.
- Paraoxonase 2 (PON2) is an enzyme with potential roles in oxidative stress and inflammation, factors implicated in stroke pathogenesis.
- Single nucleotide polymorphisms (SNPs) in genes like PON2 are potential genetic risk factors for various diseases.
Purpose of the Study:
- To investigate the association between specific single nucleotide polymorphisms (SNPs) of the paraoxonase 2 (PON2) gene and the risk of stroke.
- To determine if PON2 gene polymorphisms (C311S and G148A) are independent risk factors for stroke in the Han Chinese population of the Hunan area.
Main Methods:
- Genotyping of PON2 gene polymorphisms (C311S and G148A) using Polymerase Chain Reaction (PCR) and restriction enzyme digestion.
- Comparative analysis of genotype and allele frequencies between a control group (120 healthy individuals) and stroke patient groups (150 with cerebral hemorrhage, 180 with cerebral infarction).
Main Results:
- The C311S and G148A polymorphisms of the PON2 gene were present in the studied population.
- Allele frequencies for C/S were 0.23/0.77 and for G/A were 0.57/0.43 in the control group.
- No statistically significant differences in genotype or allele frequencies were observed between stroke patients and the control group (P > 0.05).
Conclusions:
- The C311S polymorphism of the PON2 gene shows no significant correlation with stroke in the Han Chinese population of the Hunan area.
- Neither the C/S nor the G/A alleles of the PON2 gene appear to be independent risk factors for stroke in this population.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...